Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 326-332, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (24)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, A. H. B.
Right arrow Articles by Clive, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, A. H. B.
Right arrow Articles by Clive, J. M.
Related Collections
Right arrow Laboratory Management
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1999;43:326-332.)
© 1999 American Association for Clinical Chemistry, Inc.

Articles

Impact of CK-MB testing policies on hospital length of stay and laboratory costs for patients with myocardial infarction or chest pain

Alan H. B. Wu1,a and Jonathan M. Clive2

1 Clinical Chemistry Laboratory, Hartford Hospital, 80 Seymour St., Hartford, CT, 06102. Fax 860-545-5206.

2 Office of Biostatistical Consultation, University of Connecticut Health Center, 263 Farmington Ave., Farmington, CT 06030.
a Author for correspondence.

We obtained data on hospital length of stay (LOS) and total laboratory charges for Medicare patients admitted to 82 hospitals in Massachusetts during 1994. Five Diagnosis Related Groups (DRGs) were selected: surviving acute myocardial infarction (AMI) with, and without, complications; AMI with death; angina pectoris; and chest pain. The hospitals were grouped according to their laboratory policies for testing CK-MB (e.g., frequency of assay runs; information obtained by telephone survey). The study was conducted to determine whether there was an association between turnaround times for results and LOS for cardiac DRGs. The mean LOS for AMIs with complication for 1513 patients admitted to 22 hospitals whose laboratories perform CK-MB testing once or twice daily was 8.4 days [95% confidence interval (CI): 8.2–8.7]. In contrast, the mean LOS for hospitals with CK-MB test policies of at least 3 runs daily or random-access stat was significantly (P <0.05) lower, 7.7 days (CI: 7.4–8.0 and 7.5–7.9, respectively). Overall laboratory charges were lower in the hospitals with shorter LOS. With one exception, there was no significant difference in LOS between patients with DRGs of angina pectoris or chest pain or other AMI DRGs. For AMI, a CK-MB testing policy that produces shorter turnaround times may be justified because of an association with reductions in LOS and overall laboratory costs.


Key Words: indexing terms: laboratory management • turnaround times • outcomes analysis • Diagnosis Related Group • random-access analysis • creatine kinase • isoenzymes




The following articles in journals at HighWire Press have cited this article:


Home page
 HeartHome page
R Bholasingh, R J de Winter, J C Fischer, R W Koster, R J G Peters, and G T Sanders
Safe discharge from the cardiac emergency room with a rapid rule-out myocardial infarction protocol using serial CK-MBmass
Heart, February 1, 2001; 85(2): 143 - 148.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
A. H.B. Wu, F. S. Apple, W. B. Gibler, R. L. Jesse, M. M. Warshaw, and R. Valdes Jr.
National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the Use of Cardiac Markers in Coronary Artery Diseases
Clin. Chem., July 1, 1999; 45(7): 1104 - 1121.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. J. Kost, S. S. Ehrmeyer, B. Chernow, J. W. Winkelman, G. P. Zaloga, R. P. Dellinger, and T. Shirey
The Laboratory-Clinical Interface: Point-of-Care Testing
Chest, April 1, 1999; 115(4): 1140 - 1154.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. H. Christenson and H. M. E. Azzazy
Biochemical markers of the acute coronary syndromes
Clin. Chem., August 1, 1998; 44(8): 1855 - 1864.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. H. Christenson, F. S. Apple, D. L. Morgan, G. L. Alonsozana, K. Mascotti, M. Olson, R. T. McCormack, F. H. Wians Jr., J. H. Keffer, and S.-H. Duh
Cardiac troponin I measurement with the ACCESS® immunoassay system: analytical and clinical performance characteristics
Clin. Chem., January 1, 1998; 44(1): 52 - 60.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. R. Hedges
Cardiac Enzyme Availability and Hospital Length of Stay
Clin. Chem., February 1, 1997; 43(2): 249 - 250.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.